Rasmussen encephalitis€¦ · Clinical Epilepsia partialis continua or Progressive unilateral...

27
www.laborkrone.de CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019 www.mara.de Rasmussen encephalitis Christian G. Bien Lyon, 26.05.2019

Transcript of Rasmussen encephalitis€¦ · Clinical Epilepsia partialis continua or Progressive unilateral...

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Rasmussen encephalitis

    Christian G. Bien Lyon, 26.05.2019

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Rasmussen encephalitis

    Three nagging questions

    Does my patient have Rasmussen‘s?

    If so: Immunotherapy or surgery?

    How does this disease work???

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Rasmussen encephalitis

    Three theses

    2A surgically remediable syndrome.

    Immunotherapy: only a stopgap solution

    1 RE can be securley diagnosed.

    3 RE pathogenesis: T cells and microglia (new!)

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de Steinman L, J Clin Invest 2018;128:1724

    Rasmussen encephalitis

    Objection

    Hemispherectomy=only effective seizure tx, and highly effective!

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Rasmussen encephalitis

    My background

    2001

    Since 2000:

    Rasmussen

    research

    with Hans

    Lassmann

    and Jan

    Bauer in

    Vienna

    2006: Habilitation in Bonn.

    „Pathogenesis, diagnosis and

    treatment of Rasmussen encephalitis“

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Rasmussen encephalitis

    Case report

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    • From Ukraine

    • Previously healthy

    • December 2018: focal aware seizures (clonic, L side of the body)

    • Rapid increase in sz frequency

    • March 2019: Family comes to Germany for diagnosis and treatment

    • Increasing paresis left upper and lower extremity

    • Other hospital: AED switch and IVIG therapy

    • Epilepsia partialis continua

    • April 2019: Transfer to Epilepsy Center Bethel

    Case no. 19804258

    T., T. ♂ 6 y

    History

    19804258

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de Case no. 19804258

    T., T. ♂ 6 y

    Disease onset: December 2018

    +2 months + 4 months+ 1 month

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Diagnosis

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de Bien CG, Granata T et al., Brain 2005;128:454

    T., T. ♂ 6 y

    Checking the diagnostic criteria

    Part-A-criteria (cross-sectional): all 3 must be fulfilled1. Clinical Focal seizures (+/- EPC) and Unilateral cortical deficit(s)

    2. EEG Unihemispheric slowing+/- ETP and Unilateral seizure onset

    3. MRI Unihemispheric focal cortical atrophyand >1 of the following:

    (1) Grey or white matter T2/FLAIR hyperintense signal

    (2) Hyperintense signal or atrophy of the ipsilateral caudate head

    Part-B-criteria (longitudinal/histopathological): 2/3 must be fulfilled

    1. Clinical Epilepsia partialis continua or Progressive unilateral cortical deficit(s)

    2. MRI Progressive unihemispheric focal cortical atrophy

    3. Histopathology T cell dominated encephalitis, activated microglial cells, reactive astrogliosis

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    H&E

    Case no. 19804258. H&E, orig. x400. Dr. Roland Coras, Univ. of Erlangen, Dept. of Neuropathology

    T., T. ♂ 6 y

    Brain biopsy 06.05.2019 (5 months after onset)

    H&ECD68

    CD8

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    T., T. ♂ 6 y

    Checking the diagnostic criteria

    Part-A-criteria (cross-sectional): all 3 must be fulfilled1. Clinical Focal seizures (+/- EPC) and Unilateral cortical deficit(s)

    2. EEG Unihemispheric slowing+/- ETP and Unilateral seizure onset

    3. MRI Unihemispheric focal cortical atrophyand >1 of the following:

    (1) Grey or white matter T2/FLAIR hyperintense signal

    (2) Hyperintense signal or atrophy of the ipsilateral caudate head

    Part-B-criteria (longitudinal/histopathological): 2/3 must be fulfilled

    1. Clinical Epilepsia partialis continua or Progressive unilateral cortical deficit(s)

    2. MRI Progressive unihemispheric focal cortical atrophy

    3. Histopathology T cell dominated encephalitis, activated microglial cells, reactive astrogliosis

    Olson criterion:

    2 part-A-criteria plus B3 (Histopathology)

    Bien CG, Granata T et al., Brain 2005;128:454 Olson HE et al., Epilepsia 2013;54:1753

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Rasmussen encephalitis

    Immunotherapy

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Tacrolimus

    Immunotherapy

    Effect of immuno-tx on hemispheric volume and motricity

    Bien CG et al., Neurology 2004;62:2106

    Bien CG et al., Epilepsia 2013;54:543

    No reduction of seizure frequency

    Log-rank (Mantel-Cox) Test: P=0.038

    Tac or IVIG

    Controls

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Immunotherapy

    Case example: A., N. ♂ disease onset age 5

    Case no. 18801367

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    TreatmentPyrrhic victory by immunotherapy?!

    King Pyrrhus of Epirus defeated the Romans in 279 BC at the battle of Asculum in Apulia.

    Pyrrhus remarked afterwards: “Another victory like that, and we shall be utterly ruined.”

    Preserved motor function (as a result of immuno-tx), but ongoing drug-

    resistant seizures. Hemispherectomy can hardly be offered. The patient

    remains severely impaired by the ongoing epilepsy.

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Rasmussen encephalitis

    Hemispherectomy/

    hemispherotomy

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    65%

    79% 80% 80% 81%

    92%

    0%

    20%

    40%

    60%

    80%

    100%

    Kossoff 2003(Baltimore,

    N=46)

    Schramm 2012(Bonn, N=14)

    Honavar 1982(London, N=10)

    Delalande 2007(Paris, N=25)

    Granata 2014(Mailand, N=16)

    Villemure 2006(Lausanne,

    N=12)

    Hemispherectomy/hemispherotomy

    Rasmussen encephalitis sz free outcome rates 1982-2012

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.deEpilepsy Center Bethel, Pat.-ID 60356168. - Neurosurgeon: Dr. Thilo Kalbhenn

    Hemispherectomy/hemispherotomyBethel: modified periinsular hemispherotomy

    Patient O., N. ♂

    Onset at age 5

    Preoperative MRI:

    5 y after onset

    MRI 1 mo after surgery

    2 y follow-up: Engel IA. No AED. No complication

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Hemispherotomy Immunotherapy

    Seizures long-term +++ -Sz exacerbation, status +Neurological function ↓↓ ↓↔

    Varadkar S et al., Lancet Neurol 2014;13:195

    Treatment

    Summary

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de Varadkar S, Bien CG et al., Lancet Neurol 2014;13:195

    Treatment

    Pathway

    Are seizures a relevant problem for

    the patient?

    Yes No

    Would the benefit of HE

    outweigh its risks and

    expected

    consequences?

    Is there concern about

    deterioration of

    neurological functions?

    No

    No

    specific

    treatment

    Yes

    Consider trial of

    immunotherapy

    for prevention

    of neurological

    deterioration

    No

    AEDs; consider

    trial of

    immunotherapy

    for

    improved

    seizure control

    Yes

    HE

    Re-c

    he

    ck re

    gu

    larly

    Re

    -ch

    eck r

    eg

    ula

    rly

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Rasmussen encephalitis

    Bonus Track:

    New data on pathogenesis

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    MAP-2/CD3/GrBGrB/MAP-2

    b2-M/MAP-2 Casp-3/MAP-2MHC-I

    GrB

    Bien CG et al., Ann Neurol 2002;51:311

    PathogenesisCytotoxic T cell attack against neurons

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de Tröscher AR et al., Acta Neuropathol 2019;137:619

    Pathogenesis

    Microglial nodules attract T cells via innate immunity

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Rasmussen encephalitis

    Summary

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    Diagnosis: with checklist.

    Treatment for szs: Hemispherectomy

    Slowing down of neurological deterioration: Long-term immuno-tx

    Sz exacerbation: Short-term immuno-tx

    Pathogenesis: not antibodies but T cells, attracted by microglial cells

    Rasmussen encephalitis

    Summary

  • www.laborkrone.de

    CG Bien: Rasmussen encephalitis. Lyon, 26.05.2019

    www.mara.de

    [email protected]

    Antibody diagnostic

    laboratory

    30 km apart: Bad Salzuflen

    Clinical epileptology

    130 beds

    [email protected]

    Bielefeld, Epilepsy Centre Bethel